Effect of Universal Testing and Treatment on HIV Incidence - HPTN 071 (PopART)
Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana
Virological remission after antiretroviral therapy interruption in female African HIV seroconverters
Do people living with HIV experience greater age advancement than their HIV-negative counterparts?
Prednisone for the Prevention of Paradoxical Tuberculosis-Associated IRIS
Repeat testing of low-level HIV-1 RNA: assay performance and implementation in clinical trials
Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa
Kidney Diseases Associated with Human Immunodeficiency Virus Infection
A Randomized, Controlled Trial of a Behavioral Weight Loss Program for HIV-Infected Patients
CD32a is a marker of a CD4 T-cell HIV reservoir harbouring replication-competent proviruses
Life expectancy in HIV-positive persons in Switzerland: matched comparison with general population
Successful Prevention of Transmission of Integrase Resistance in the Swiss HIV Cohort Study
Immunologic Biomarkers, Morbidity, and Mortality in Treated HIV Infection
Rosuvastatin slows progression of subclinical atherosclerosis in patients with treated HIV infection
Antiretroviral therapy for the prevention of HIV-1 transmission
HIV Transmission Risk Persists During the First 6 Months of Antiretroviral Therapy
Review of the Efficacy, Safety, and Pharmacokinetics of Raltegravir in Pregnancy
Use of Abacavir and Risk of Cardiovascular Disease Among HIV-Infected Individuals
Patterns of Cardiovascular Mortality for HIV-Infected Adults in the United States: 1999 to 2013
Adjunctive Dexamethasone in HIV-Associated Cryptococcal Meningitis
Outcomes of HIV-associated Hodgkin lymphoma in the era of antiretroviral therapy
CD8 T-Cell Expansion and Inflammation Linked to CMV Coinfection in ART-treated HIV Infection
Ongoing HIV Replication Replenishes Viral Reservoirs During Therapy
Incidence and progression of coronary artery calcium in HIV-infected and HIV-uninfected men
Levels of intracellular HIV-DNA in patients with suppressive antiretroviral therapy
Course and Clinical Significance of CD8+ T-Cell Counts in a Large Cohort of HIV-Infected Individuals
Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients
Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1
HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007-12: impact on susceptibility to first-line strategies
Published by Pedro CAHN
Updated: 15 June, 2015
The study describes the prevalence of transmitted drug resistance among 1,318 French patients diagnosed at the time of primary HIV-1 infection in 2007-2012. HIV-1 resistance-associated mutations were characterized using both the 2009 WHO list of mutations and the French ANRS algorithm. A genotypic susceptibility score was estimated for each first-line recommended antiretroviral therapy combination. Patients were mainly MSM (72.6%). Non-B subtypes were identified in 33.7% of patients.
The proportion of transmitted drug resistance was estimated as 11.7% (95% CI 10.0-13.5). The prevalence of PI (NRTI), first-generation NNRTI and etravirine/rilpivirine resistance-associated mutations were 2.5%, 5.2%, 3.9% and 3.2%, respectively. Single, dual and triple class resistance was found in 9.6%, 1.0% and 1.1% of cases, respectively. Additionally, 5/331 strains isolated in 2010-2012 had integrase inhibitor-related resistance-associated mutations (isolated E157Q mutation in all cases). Transmitted drug resistance was more common among MSM than in other groups (12.9% versus 8.6%, p = 0.034), and in case of B versus non-B subtype infections (13.6% versus 7.9%, p = 0.002). The proportions of fully active combinations were ≥ 99.2%, ≥ 9 7.3% and ≥ 95.3% for PI, integrase inhibitor, and NNRTI-based regimens, respectively. In 2010-2012, the proportion of fully active efavirenz-based antiretroviral therapy was lower in cases of subtype B versus non-B infection (p = 0.021).
Compared to previous results, the proportion of NRTI and first-generation NNRTI-related transmitted drug resistance has continued to decline in French seroconverters. However, subtype B-infected MSM could drive the spread of resistant HIV strains.